NASDAQ:FCSC

Fibrocell Science (FCSC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$3.00
$3.00
50-Day Range
$3.00
$3.00
52-Week Range
$1.45
$3.28
Volume
N/A
Average Volume
78,673 shs
Market Capitalization
$29.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FCSC stock logo

About Fibrocell Science Stock (NASDAQ:FCSC)

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

FCSC Stock News Headlines

Best Data Science Bootcamps Online In 2024
Science & Tech News
Protect Yourself While There’s Still Time …
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
Oramed Pharmaceuticals
See More Headlines
Receive FCSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2019
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FCSC
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
$-10,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$0.98 per share

Miscellaneous

Free Float
N/A
Market Cap
$29.28 million
Optionable
Optionable
Beta
1.67
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John Michael Maslowski (Age 44)
    Pres, CEO & Director
  • Mr. Sean D. Buckley (Age 37)
    VP of Bus. Admin. & Corp. Sec.
  • Mr. Robert G. Partridge
    VP of Global Marketing, Communications and Investor Relations
  • Ms. Michele Mchugh-Mazzatta
    VP of Sales
  • Dr. Pierre Compte
    Managing Director of Switzerland

FCSC Stock Analysis - Frequently Asked Questions

How were Fibrocell Science's earnings last quarter?

Fibrocell Science Inc (NASDAQ:FCSC) released its quarterly earnings results on Wednesday, August, 14th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of ($0.18) by $1.30. The business earned $21.79 million during the quarter.

When did Fibrocell Science's stock split?

Fibrocell Science's stock reverse split on the morning of Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Fibrocell Science own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Neurotrope (NTRP), Verastem (VSTM), Synergy Pharmaceuticals (SGYP) and Agile Therapeutics (AGRX).

This page (NASDAQ:FCSC) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners